Inovio Pharmaceuticals, INC 8-K filings

Inovio Pharmaceuticals announced second quarter 2026 financial results, highlighting progress in the INO-3107 BLA review with a PDUFA date set for October 30, 2026, alongside positive Phase 3 data for VGX-3100 from its partner ApolloBio.

Inovio Pharmaceuticals announced the pricing of a public offering of common stock and warrants, expecting to raise approximately $20.0 million.

Inovio Pharmaceuticals provides an estimated cash and cash equivalents of $36.7 million as of June 30, 2026, subject to final financial closing procedures.

Inovio Pharmaceuticals announced board-approved amendments to its bylaws, establishing a Lead Independent Director role and clarifying the Chairman's position, alongside reporting results from its 2026 Annual Meeting of Stockholders.

Inovio Pharmaceuticals announced first quarter 2026 financial results, highlighting the ongoing FDA review of its Biologics License Application for INO-3107 with a target PDUFA date of October 30, 2026, and updated cash runway into Q1 2027.

Inovio Pharmaceuticals has priced an underwritten public offering of common stock and warrants expected to raise approximately $17.5 million in gross proceeds.

Inovio Pharmaceuticals, Inc. has suspended and terminated the prospectus for its at-the-market offering, halting further stock sales.

Inovio Pharmaceuticals announced its BLA for INO-3107 was accepted by the FDA with an October 2026 PDUFA date, alongside Q4 and full-year 2025 financial results showing reduced operating expenses and net loss.

Inovio Pharmaceuticals, Inc. has amended its Series A Warrants, extending their expiration date from January 28, 2026, to March 31, 2026.

Inovio Pharmaceuticals announced the FDA's acceptance of its Biologic License Application for INO-3107, an investigational immunotherapy for recurrent respiratory papillomatosis in adults, though accelerated approval eligibility is under review.

Inovio Pharmaceuticals, Inc. announced the pricing of a public offering of common stock, raising approximately $26.5 million in net proceeds to fund its operations.

Inovio Pharmaceuticals announced the completion of its Biologics License Application submission for INO-3107 and reported its third-quarter 2025 financial results, including a significant increase in net loss.

Inovio Pharmaceuticals announced its second quarter 2025 financial results, highlighting progress on its INO-3107 Biologics License Application submission and a strengthened balance sheet.

Inovio Pharmaceuticals, Inc. has announced the pricing of an underwritten public offering to raise approximately $25 million through the sale of common stock and accompanying Series A and Series B warrants.

Inovio Pharmaceuticals held its 2025 Annual Meeting of Stockholders on May 20, 2025, and all proposals were approved.

Inovio Pharmaceuticals announces its Q1 2025 financial results and provides an update on the progress of its INO-3107 program and DMAb technology.

INOVIO reports significant progress towards submitting a BLA for INO-3107, resolves manufacturing issues, and announces its financial results for the fourth quarter and full year 2024.

Inovio Pharmaceuticals has priced a public offering of 10 million shares of common stock and accompanying warrants, expected to generate $30 million in gross proceeds.

Inovio Pharmaceuticals announced its Q3 2024 financial results, highlighting progress with its lead candidate INO-3107 and providing updates on other pipeline developments.

Inovio Pharmaceuticals has entered into an agreement to sell up to $60 million of its common stock through an at-the-market offering.

Inovio Pharmaceuticals reported its second quarter 2024 financial results, highlighted by a delay in the BLA submission for INO-3107 due to a manufacturing issue, but also progress in other clinical programs and a strengthened balance sheet.

Inovio Pharmaceuticals granted performance-based restricted stock units to its named executive officers and held its 2024 annual meeting of stockholders.

Inovio Pharmaceuticals announced its first quarter 2024 financial results and provided updates on its clinical programs, including the planned BLA submission for INO-3107.

Inovio Pharmaceuticals has priced an underwritten offering to raise approximately $36 million through the sale of common stock and pre-funded warrants.

Inovio Pharmaceuticals has executed a 1-for-12 reverse stock split, effective January 24, 2024, to consolidate its outstanding shares.

Inovio Pharmaceuticals' stockholders have approved a reverse stock split proposal, allowing the board to enact a split between 1-for-10 and 1-for-50 within the next year.